In 2026, Alzheimer's blood tests screen for amyloid and p-tau, while Tauklarify tau PET maps tau tangles for staging and treatment decisions. Blood comes first because it is simpler, and PET or spinal fluid still confirms positive or unclear blood results. Tauklarify (florquinitau F18 injection) is a tracer injected before a brain scan.
It highlights neurofibrillary tangles, twisted tau fibers tied to Alzheimer's. The FDA approved it on Aug. 14, 2026, for cognitively impaired adults evaluated for Alzheimer's, according to the Enigma Biomedical approval notice.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What Tauklarify PET shows
- How accurate are blood tests?
- When blood results mislead
- How memory clinics use both tests
What Tauklarify PET shows
Approval rested on two studies with 617 scans read by five blinded readers per study, according to Practical Neurology's report. Positive agreement was 68%-88% and negative agreement was 93%-99% versus cognitive-plus-amyloid-PET reference.
Enigma Biomedical limits use to Alzheimer's evaluation. Safety and effectiveness are not established for other tau diseases. A scan alone neither confirms nor rules out tau pathology.
How accurate are blood tests?
Psychiatric Times, summarizing FDA records, says the first clearance was Fujirebio Lumipulse G pTau217/β-amyloid 1-42 ratio on May 16, 2025. It is for symptomatic adults age 55 and older, according to Psychiatric Times summary of FDA data. In that study of 499 patients, 91.7% of positives and 97.3% of negatives matched PET or spinal fluid, with under 20% unclear. Forbes reports four blood tests were cleared by August 2026.
Roche Elecsys pTau181 serves primary-care rule-out with about 98% negative predictive value in 312 patients. C2N PrecivityAD2 is for ages 40 and older and showed 97.6% positive and 93.1% negative predictive values in 1,142 patients. The Alzheimer's Association issued its first blood-biomarker guideline on July 29, 2025. It applies only to cognitively impaired patients seen in specialty memory care. It asks for at least 90% sensitivity plus 75% specificity for triage, and 90% for both to replace PET or spinal fluid.
When blood results mislead
Severe kidney failure is the most common confounder and can cause false-positive p-tau217. Morbid obesity also shifts levels.
Psychiatric Times notes clinicians must weigh kidney function, weight, and exam findings when reading results. Tell the clinic about kidney disease, dialysis, recent illness, and weight change. Ask whether a new prescription, dehydration, or missed dialysis could have raised the value before repeating the test.
How memory clinics use both tests
Blood shows whether amyloid or p-tau is present, while tau PET maps tangle amount and spread for staging and treatment choices. PET costs more, and positive or unclear blood still needs PET or spinal-fluid confirmation, according to Forbes via ApexNews reporting.
Use this order at a visit. Do not start treatment or rule out Alzheimer's on blood alone.
- Ask if your case meets memory-clinic triage rules
- Share kidney labs and weight history before blood testing
- Plan PET or spinal fluid if blood is positive or unclear
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: Accuracy, Limits, and Evidence Gaps for Memory Clinic Patients
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Accuracy, Limits, and Evidence Gaps for Memory Clinic Patients
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: Accuracy, Limits, and Evidence Gaps for Memory Clinic Patients
